Transcript The Network of European Neuroscience Schools

Research in Neurosciences,
A European Perspective
Peter Paul De Deyn
Scientific Director Institute Born-Bunge
The Network of European
Neuroscience Schools
The Network of European Neuroscience Schools (NENS)
was founded in 2003 and represents over 150 of those
graduate schools and programmes across ca. 30 European
countries that offer Masters, MD, PhD and doctoral
degrees in neuroscience. NENS is a formal structure within
the Federation of European Neuroscience Societies (FENS).
The Network of European
Neuroscience Schools
The Network of European Neuroscience Schools (NENS)
was founded in 2003 and represents over 150 of those
graduate schools and programmes across ca. 30 European
countries that offer Masters, MD, PhD and doctoral
degrees in neuroscience. NENS is a formal structure within
the Federation of European Neuroscience Societies (FENS).
European Neuroscience and
Society Network
European network for interdisciplinary discussions of the
social implications of the neurosciences. Funded by the
European Science Foundation
The Network of European
Neuroscience Schools
The Network of European Neuroscience Schools (NENS)
was founded in 2003 and represents over 150 of those
graduate schools and programmes across ca. 30 European
countries that offer Masters, MD, PhD and doctoral
degrees in neuroscience. NENS is a formal structure within
the Federation of European Neuroscience Societies (FENS).
The Network of European
Neuroscience Schools
Publication Analysis 1997-2008
Clinical Neurosciences
European Commission – Health
Research - Brain Research
The strategic guidance for our funding of brain research is
the 7th Framework Programme on Research and Technical
Development (FP7) implemented through so-called Specific
Programmes (SPs). Health research in general and brain
research in particular is implemented in the Specific
Programme Cooperation. Support for infrastructures is
provided through the Specific Programme Capacities. The
well-established Marie-Curie fellowships are funded
through the Specific Programme People and the European
Research Council is funded through the Specific
Programme Ideas.
European Commission – Health
Research - Brain Research
Brain research is supported in the Seventh Framework
Programme (FP7; 2007-2013), which includes an activity
on ‘Research on the brain and related diseases’ under the
theme ‘Health’. This activity has a particular emphasis on
translational research, meaning translation of basic
discoveries into clinical applications. In the first three FP7
calls, 30 projects were funded under this activity for a total
of EUR 135 million. Research relevant to the brain and the
nervous system is also addressed in other areas of the
current ‘Health’ theme, where an additional 49 research
projects received funding for about EUR 247 million.
Promoting Breakthrough
Therapies
across Europe
Michel Goldman, MD,PhD
Executive Director
Belgian Brain Congress 2010
Innovative Medicines Initiative:
the Largest PPP in Life Sciences R&D
2 Billion Euro
1 Billion €
Public
1 Billion €
Partnership
Private
IMI: Topics for the First Call
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
Improved predictivity of immunogenicity
Non-genotoxic carcinogenesis
2.5m/2y plus
Expert systems for in silico toxicity prediction
Improved predictivity of non-clinical safety evaluation
Qualification of Translational safety biomarkers
Strengthening the monitoring of benefit/risk
Islet cell research
Surrogate markers for vascular endpoints
Pain research
New tools to develop novel therapies in psychiatric disorders
Neurodegenerative disorders
Understanding severe asthma
COPD Patient Reported Outcomes
European Medicines Research Training Network
Safety sciences for medicines training programme
Pharmaceutical medicine training programme
Integrated medicines development training programme
Pharmacovigilance training programme
13m/ 5y
10m/ 3y
5m/ 5y
10m/ 3y
21m/ 5y
15m/ 5y
10m/ 5y
20m/ 5y
7.5m/ 5y
10m/ 5y
7.5m/ 5y
12.5m/ 5y
2m/ 1y + 8m/5y
5m/ 7y
3m/ 5y
4m/ 5y
3m/ 5y
3.5m/ 5y
EFPIA Commitment: 172.5m Euros, typical project ~15m,
5-10 EFPIA partners/project, majority of 5y duration
IMI: Neurodegenerative Disorders
Bridging the preclinical /clinical
Clinical outcome studies in the neurodegeneration area are notoriously long and
expensive. In order to accelerate the successful development of molecules for the
treatment of Neurodegenerative disorders, it is essential to improve the predictive
value of animal models, identify pharmacodynamic markers of drug response,
pharmacodynamic models that allow early prediction of efficacy and markers to
aid stratification of the patient population. The success of this will be dependent
on the partnership of preclinical and clinical scientists to adopt an integrated
approach to ensure effective translation of efficacy from bench to bedside and
visa versa. This translational science/medicine approach will allow the rapid
identification and accelerated development of successful candidate molecules as
well as terminating efforts earlier on those unlikely to offer clinical benefit.
IMI Projects on Brain
Disorders
Alzheimer’s disease
Pilot project: Addneuromed
Ongoing project: Pharmacog (total budget: 27.7 M €)
Schizophrenia and depression
Ongoing project: Newmeds (total budget: 24.0 M €)
Autism
Call for Proposals to be released end October 2010
Prediction of cognitive properties of new
drug candidates for neurodegenerative
diseases in early clinical development.
PHARMA-COG
Area 4.2 - Support to policies
Description and scope of topic 4.2-8:
HEALTH-2010.4.2-8: Coordination action in support of the implementation
by participating States of a Joint Programming Initiative for combating
neurodegenerative diseases, in particular Alzheimer's disease.
Following the Commission's Communication on Joint Programming to tackle Europe's major
societal challenges, the Competitiveness Council, called for a common commitment of EU
Member States (MS) to fight Alzheimer's disease and other neurodegenerative diseases.
The successful coordination action must support the implementation of a pilot Joint
Programming Initiative by proposing innovative ways of pooling national expertise and
resources and establishing closer and robust collaborations among the participating States
in the field of neurodegenerative diseases, in particular Alzheimer's disease. Applicants
must be national/regional agencies and/or ministries funding activities related to
neurodegenerative diseases.
Funding scheme: Coordination and Support Action (Coordinating Action).
The European Brain Council (EBC), established in 2002,
involves all major European organizations involved in
brain-related issues ranging from scientific and clinical
societies, to industry and patients organizations. EBC together with its member organizations – promotes brain
research in Europe; this will lead to new therapeutic and
diagnostic tools and together with improved education and
information. An important goal is to improve the quality of
life of those European citizens living with brain-related
diseases as well as of their carers.
I: Development, plasticity & ageing of the brain in health & disease
II. Mind – brain relationship and mental disorders
III. Degeneration & repair in the Brain
IV. Revealing pain mechanisms & their control
V. Rehabilitation, psychological care & prevention
VI. Sensory systems & autonomic disturbances
VII. Towards a better diagnostic & therapeutic approach: enabling
technologies
Vision UA
Institute Born-Bunge

Institute Bunge (clinic and research) :
1934-1962-1979




“.. In order to establish a center for surgical and medical
research where full diagnostic research could be combined with
scientific research.”
Travaux de l’Institut Bunge Vol I, 1936.
Born-Bunge Foundation (research) :
1963-2004
Institute Born-Bunge (research) : from
2005
Ludo van Bogaert and Charles Poser 1955
Prof. Armand Lowenthal
1919-2001
Intrathecal IgG synthesis in MS
Micro-Eletrophoresis in Agar Gel of Proteins of the Cerebrospinal Fluid and Central Nervous
System 1959. D. Karcher, M. van Sande and A. Lowenthal. Institute of Tropical Medicine, Antwerp, and
Institute Bunge, Berchem Antwerp, Belgium Journal of Biochemistry 1959; 4: 135-140
Prof. Armand Lowenthal
Prof. J.J. Martin
Neurometabolic storage diseases (together with Prof. Ceuterick-De Groote)
Neuromuscular disorders
Detailed anatomical study of the thalamus
Neuropathological study of dementia

Brief presentation IBB Laboratories
and groups
Laboratory for Electrobiology
Laboratory for Neurobiology
Laboratory for Theoretical
Neurobiology
En: Ongoin g research on the physiology of brain-computer inte rfaces
Laboratory for Neurochemistry &
Behaviour
Laboratory for Neurochemistry &
Behaviour
Laboratory for Neurochemistry &
Behaviour
Reference for Biological Markers of Memory disorders
LNG: Behavioural research and
pharmacological modulation in rodent
models of dementia
Van Dam D. & De Deyn P.P. Drug development in dementia: the role of rodent models. Nature
Reviews Drug Discovery (2006)
IBB- Laboratories for
Neurogenetics

Three research groups active in the investigation of
complex neurological diseases of the peripheral and central
nervous system



Peripheral Neuropathies
 Vincent Timmerman
Neurogenetics
 Peter De Jonghe
Neurodegenerative Brain diseases
 Christine Van Broeckhoven
Peripheral Neuropathy group
About nerves, pedigrees and genes
Neurogenetics group
IBB- Neurodegenerative Brain
diseases Group
Neurodegenerative
Brain diseases Group
IBB-
Frontotemporal Dementia with Ubiquitin-positive inclusions
Key publications

Cruts,M., Gijselinck,I., van der Zee,J., Engelborghs,S., Wils,H., Pirici,D., Rademakers, R.,
Vandenberghe,R., Dermaut,B.,Martin,J-J., van Duijn,C., Peeters,K., Sciot,R., Santens,P., De
Pooter,T., Mattheijssens,M., Van den Broeck,M.,Cuijt,I.,Vennekens,K., De Deyn,P.P, KumarSingh,S., Van Broeckhoven,C. Null mutations in progranulin cause ubiquitin-positive
frontotemporal dementia linked to chromosome 17q21, Nature, 442(7105):920-924 (2006)

van der Zee,J., Rademakers,R., Engelborghs,S., Gijselinck,I., Bogaerts,V., Vandenberghe,R.,
Santens,P., Caekebeke,J., De Pooter,T., Peeters,K., Lübke,U., Van den Broeck,M., Martin,J-J.,
Cruts,M., De Deyn,P.P., Van Broeckhoven,C., Dermaut,B.: A Belgian Ancestral Haplotype
Harbors a Highly Prevalent mutation for 17q21-Linked Tau-negative FTLD. Brain 129(4): 841852 (2006)

Pirici,D., van der Zee,J., Vandenberghe,R., Rademakers,R., Dermaut,B., Cruts,M.,
Vennekens,K., Cuijt,I., Lübke,U., Ceuterick,C., Martin,J-J., Van Broeckhoven,C., KumarSingh,S.: Characterization of ubiquitinated intraneural inclusions in a novel Belgian FTLD
family. Journal of Neuropathology & Experimental Neurology 65(3): 289-301 (2006)
FTDU-17 gene is progranulin
0
1
UTR





2
3
P
4
G
F
5
6
B
8
7
A
C
9
D
10
E
11
1 UTR gDNA
2
mRNA
593 codons
PGRN is located at 17q21.32, 1.7 Mb centromeric of MAPT
Growth modulatory activity
Role in several physiological and pathological processes
(development, wound repair, inflammation and
tumorigenesis)
Cysteine-rich polypeptide
7.5 x 12-cysteine granulin motif
Function in brain?
Baker et al. and Cruts et al. Nature 2006
Laboratory for Ultrastructural
neuropathology & Biobank
IBB BIOBANK
Co-ordinator: PP De Deyn
Brain
Neuromuscular specimens / skin
Cerebrospinal fluid
Blood - plasma - serum
DNA, Cell cultures
Human & animal
Task Forces
TF 3
TF 1
Neuromuscular Disorders
Responsible: C. Ceuterick
P. De Jonghe/ V. Timmerman
K. Claeys, L. Heytens
Consultant: J.J. Martin
(NMRC UZA, LUN)
TF 2
Prion Diseases
Responsible: P. Cras
(Lab. of Neurobiology)
CNS Neurodegenerative
Disorders (dementia/park)
Responsibles:
C. Van Broeckhoven &
PP. De Deyn
S. Engelborghs
S. Kumar-Singh
Consultant: J.J. Martin
(LNG, LNB)
Impact factors of IBB publications
in 2009
IBB Publications 2009
35
published (n=78)
in press (n=14)
number of publications
30
25
total n=92
20
15
10
5
0
no IF
0-2
2-4
4-6
impact factors
6-8
8-10
> 10